Krystal Biotech grants director 1,187 options

Krystal Biotech, Inc. granted director Christopher Mason stock options and RSUs that fully vest in 2027, with no sales or purchases reported.

Rhea-AI Filing Summary

Krystal Biotech, Inc. (symbol: KRYS) is the issuer of record for a Form 4 filing submitted to the SEC. Mason Christopher reported acquisition or exercise transactions in this Form 4 filing.

Krystal Biotech, Inc. director Christopher Mason received equity awards in the form of stock options and restricted stock units. On September 14, 2026 he was granted 1,187 stock options to buy common stock at $340.03 per share, expiring September 13, 2036, and 471 restricted stock units, each representing one share of common stock. Both the options and RSUs vest in full on September 14, 2027, subject to his continued service on the Board of Directors and potential earlier vesting under the company’s Non-Employee Director Compensation Policy. No Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Grant/Award: 1,658 shares

Grant/Award 2 txns

Insider Mason Christopher

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	1,187	$0.00	$0.00
Grant/Award	Restricted Stock Units F2, F3	471	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 1,187 contracts (Direct); Restricted Stock Units — 471 contracts (Direct)

Footnotes (3)

1. F1. The stock options vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant.
2. F2. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
3. F3. The RSUs vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant.

Key Figures

Stock options granted: 1,187 options Option exercise price: $340.03 per share Option expiration date: September 13, 2036 +4 more

7 metrics

Stock options granted 1,187 options Director grant dated September 14, 2026

Option exercise price $340.03 per share Exercise price for 1,187 options granted September 14, 2026

Option expiration date September 13, 2036 Expiration for stock options granted to Christopher Mason

Restricted stock units granted 471 RSUs Director grant dated September 14, 2026

Vesting date for options and RSUs September 14, 2027 Full vesting subject to continued Board service and earlier vesting conditions

Shares following option grant 1,187 derivative securities Stock options held directly after the September 14, 2026 grant

Shares following RSU grant 471 derivative securities Restricted stock units held directly after the September 14, 2026 grant

Key Terms

Restricted Stock Units, contingent right, Non-Employee Director Compensation Policy

3 terms

Restricted Stock Units financial

"The RSUs vest in full on September 14, 2027, subject to continued service"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

contingent right financial

"Each restricted stock unit ("RSU") represents a contingent right to receive"

Non-Employee Director Compensation Policy financial

"circumstances described in the Company's Non-Employee Director Compensation Policy"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did KRYS grant to director Christopher Mason on September 14, 2026?

On September 14, 2026, Christopher Mason received 1,187 stock options with an exercise price of $340.03 per share and 471 restricted stock units, each RSU representing a contingent right to receive one share of Krystal Biotech, Inc. common stock.

When do Christopher Mason’s new KRYS stock options and RSUs vest?

Both the 1,187 stock options and the 471 restricted stock units granted to Christopher Mason vest in full on September 14, 2027, subject to his continued service on Krystal Biotech, Inc.’s Board of Directors and to earlier vesting in certain circumstances under the company’s Non-Employee Director Compensation Policy.

What is the exercise price and expiration date of Christopher Mason’s KRYS stock options?

The stock options granted to Christopher Mason on September 14, 2026 cover 1,187 shares of Krystal Biotech, Inc. common stock at an exercise price of $340.03 per share and are scheduled to expire on September 13, 2036, unless exercised or forfeited earlier under their terms.

How many KRYS shares can Christopher Mason receive from his new restricted stock units?

Christopher Mason received 471 restricted stock units, and each RSU represents a contingent right to receive one share of Krystal Biotech, Inc. common stock, subject to vesting conditions described in the company’s Non-Employee Director Compensation Policy as in effect on the grant date.

Are Christopher Mason’s KRYS equity awards granted under a Rule 10b5-1 trading plan?

No. The filing indicates that the Rule 10b5-1 checkbox is not marked, meaning no Rule 10b5-1 trading plan is reported in connection with the stock option and restricted stock unit grants to director Christopher Mason on September 14, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/16/2026 - 08:02 PM Accepted by SEC EDGAR 09/16/2026 - 08:01 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mason Christopher

(Last) (First) (Middle)

C/O KRYSTAL BIOTECH, INC.

2100 WHARTON STREET, SUITE 701

(Street)

PITTSBURGH PENNSYLVANIA 15203

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Krystal Biotech, Inc. [ KRYS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$340.03	09/14/2026		A		1,187		(1)	09/13/2036	Common Stock	1,187	$0	1,187	D
Restricted Stock Units	(2)	09/14/2026		A		471		(3)	(3)	Common Stock	471	$0	471	D

Explanation of Responses:

1. The stock options vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant.

2. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock.

3. The RSUs vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant.

Remarks:

	/s/ Krish Krishnan, as attorney-in-fact for Christopher Mason	09/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)